中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共2条，第1-2条 帮助

已选(0)清除 条数/页：   排序方式：
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study 期刊论文
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021
作者:  Wang, Wenxian;  Gu, Xiaodong;  Wang, Liping;  Pu, Xingxiang;  Feng, Huijing;  Xu, Chunwei;  Lou, Guangyuan;  Shao, Lan;  Xu, Yibing;  Wang, Qian;  Wang, Siyuan;  Gao, Wenbin;  Zhang, Yiping;  Song, Zhengbo
收藏  |  浏览/下载：72/0  |  提交时间：2022/01/10
Non-small cell lung cancer  PD-L1  Immune checkpoint inhibitor  Immune-related adverse event  
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China 期刊论文
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021
作者:  Zhang, Xiangyu;  Zeng, Liang;  Li, Yizhi;  Xu, Qinqin;  Yang, Haiyan;  Lizaso, Analyn;  Mao, Xinru;  Jin, Ren'an;  Zeng, Yu;  Li, Qinglin;  Wang, Jianbo;  Li, Yang;  Zhang, Yongchang;  Yang, Nong
收藏  |  浏览/下载：56/0  |  提交时间：2021/03/15
Anlotinib  Immunotherapy  Programmed death 1 inhibitor  Lung cancer